Shanghai Yizhong Pharmaceutical Co Ltd (688091)

Currency in CNY
72.26
-0.73(-1.00%)
Delayed Data·

688091 Financial Summary

Key Ratios

P/E Ratio1,715.41
Price/Book10.25
Debt / Equity0.76%
Return on Equity0.72%
Dividend Yield0.00%
EBITDA-4.85M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.04%
Dividend Yield
-
Industry Median 1.43%
Annualised payout
-
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
0.11 / --
Revenue / Forecast
89.28M / --
EPS Revisions
Last 90 days

FAQ

What were Shanghai Yizhong Pharmaceutical's earnings for the latest quarter?

The Shanghai Yizhong Pharmaceutical EPS (TTM) is 0.04. Shanghai Yizhong Pharmaceutical reported sales of 89.28, net income of 23.82, and EPS of 0.11 for the latest quarter.

What was Shanghai Yizhong Pharmaceutical's net income for the latest quarter?

Shanghai Yizhong Pharmaceutical's net income for the latest quarter was 23.82.

How did Shanghai Yizhong Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 71.03 in the previous quarter to 89.28 in the latest quarter, and net income moved from 14.19 to 23.82 compared to the previous quarter.

What is Shanghai Yizhong Pharmaceutical's net profit margin on a TTM basis?

Shanghai Yizhong Pharmaceutical's trailing twelve months (TTM) net profit margin is 4.02%.

How does Shanghai Yizhong Pharmaceutical's debt to equity ratio compare to industry standards?

Shanghai Yizhong Pharmaceutical's total debt-to-equity ratio is 0.76%.

What is Shanghai Yizhong Pharmaceutical's return on investment on a TTM basis?

Shanghai Yizhong Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 0.72%.

Did Shanghai Yizhong Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Shanghai Yizhong Pharmaceutical's net change in cash was -64.87 million.

What were Shanghai Yizhong Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Shanghai Yizhong Pharmaceutical reported total assets of 1,494.18 million and total liabilities of 43.64 million.

How has Shanghai Yizhong Pharmaceutical's total revenue grown this year?

Shanghai Yizhong Pharmaceutical's total revenue was 71.03 in the previous quarter and 89.28 in the latest quarter.

What is Shanghai Yizhong Pharmaceutical's gross margin on a TTM basis?

Shanghai Yizhong Pharmaceutical's trailing twelve months (TTM) gross margin is 83.64%.

What was Shanghai Yizhong Pharmaceutical's revenue per share for the latest quarter?

Shanghai Yizhong Pharmaceutical's revenue per share for the latest quarter was 6.55.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.